Total Payments
$85,007
2024 Payments
$6,744
Companies
39
Transactions
1,376
Medicare Patients
3,852
Medicare Billing
$683,086
Payment Breakdown by Category
Other$58,229 (68.5%)
Food & Beverage$23,110 (27.2%)
Travel$3,095 (3.6%)
Consulting$442.50 (0.5%)
Education$130.30 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $58,229 | 48 | 68.5% |
| Food and Beverage | $23,110 | 1,316 | 27.2% |
| Travel and Lodging | $3,095 | 5 | 3.6% |
| Consulting Fee | $442.50 | 1 | 0.5% |
| Education | $130.30 | 6 | 0.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ITI, Inc. | $21,965 | 75 | $0 (2023) |
| Allergan, Inc. | $14,672 | 59 | $0 (2021) |
| Sunovion Pharmaceuticals Inc. | $10,178 | 67 | $0 (2022) |
| ABBVIE INC. | $9,984 | 98 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $6,550 | 186 | $0 (2024) |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $3,559 | 20 | $0 (2024) |
| Teva Pharmaceuticals USA, Inc. | $2,584 | 151 | $0 (2024) |
| Indivior Inc. | $2,218 | 25 | $0 (2024) |
| Otsuka America Pharmaceutical, Inc. | $2,076 | 139 | $0 (2024) |
| Alkermes, Inc. | $1,783 | 72 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $6,744 | 189 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) ($3,559) |
| 2023 | $12,029 | 200 | ITI, Inc. ($6,137) |
| 2022 | $15,665 | 193 | ITI, Inc. ($9,595) |
| 2021 | $13,066 | 160 | ITI, Inc. ($4,112) |
| 2020 | $9,873 | 167 | ITI, Inc. ($2,121) |
| 2019 | $12,121 | 203 | Janssen Pharmaceuticals, Inc ($4,902) |
| 2018 | $11,079 | 151 | Sunovion Pharmaceuticals Inc. ($5,500) |
| 2017 | $4,431 | 113 | Allergan Inc. ($2,651) |
All Payment Transactions
1,376 individual payment records from CMS Open Payments — Page 1 of 56
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $25.60 | General |
| Category: PSYCHIATRY | ||||||
| 12/17/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $3.89 | General |
| Category: PSYCHIATRY | ||||||
| 12/13/2024 | Tris Pharma Inc | Dyanavel XR (Drug) | Food and Beverage | In-kind items and services | $16.30 | General |
| Category: ADHD | ||||||
| 12/10/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $12.34 | General |
| Category: Neuropsychiatry | ||||||
| 12/10/2024 | Otsuka America Pharmaceutical, Inc. | ABILIFY ASIMTUFII (Drug) | Food and Beverage | In-kind items and services | $7.37 | General |
| Category: PSYCHIATRY | ||||||
| 12/09/2024 | Axsome Therapeutics, Inc. | Auvelity (Drug) | Food and Beverage | In-kind items and services | $28.43 | General |
| Category: Psychology/Psychiatric | ||||||
| 12/04/2024 | Supernus Pharmaceuticals, Inc. | Qelbree (Drug) | Food and Beverage | In-kind items and services | $22.02 | General |
| Category: VILOXAZINE HYDROCHLORIDE | ||||||
| 12/03/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $22.29 | General |
| Category: PSYCHIATRY | ||||||
| 12/02/2024 | Janssen Pharmaceuticals, Inc | INVEGA SUSTENNA (Drug) | Food and Beverage | In-kind items and services | $21.35 | General |
| Category: Neuroscience | ||||||
| 11/26/2024 | Janssen Pharmaceuticals, Inc | SPRAVATO (Drug) | Food and Beverage | In-kind items and services | $15.14 | General |
| Category: Neuroscience | ||||||
| 11/24/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $13.60 | General |
| Category: PSYCHIATRY | ||||||
| 11/21/2024 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $17.80 | General |
| Category: PSYCHIATRY | ||||||
| 11/19/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $14.39 | General |
| Category: Neuropsychiatry | ||||||
| 11/19/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $1.79 | General |
| Category: Neuropsychiatry | ||||||
| 11/18/2024 | Noven Therapeutics, LLC | Xelstrym (Drug), Secuado | Food and Beverage | In-kind items and services | $18.65 | General |
| Category: ADHD | ||||||
| 11/18/2024 | Alkermes, Inc. | ARISTADA (Drug), ARISTADA, ARISTADA | Food and Beverage | In-kind items and services | $3.25 | General |
| Category: CNS | ||||||
| 11/14/2024 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $10.36 | General |
| Category: PSYCHIATRY | ||||||
| 11/13/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $22.04 | General |
| Category: PSYCHIATRY | ||||||
| 11/13/2024 | Bausch Health US, LLC | APLENZIN (Drug) | Food and Beverage | In-kind items and services | $20.64 | General |
| Category: Neurology | ||||||
| 11/12/2024 | Otsuka America Pharmaceutical, Inc. | ABILIFY MAINTENA (Drug), ABILIFY ASIMTUFII | Food and Beverage | In-kind items and services | $29.95 | General |
| Category: PSYCHIATRY | ||||||
| 11/12/2024 | Teva Pharmaceuticals USA, Inc. | UZEDY (Drug) | Food and Beverage | In-kind items and services | $18.82 | General |
| Category: Neurology | ||||||
| 11/08/2024 | Tris Pharma Inc | Onyda XR (Drug) | Food and Beverage | In-kind items and services | $19.06 | General |
| Category: ADHD | ||||||
| 11/06/2024 | Takeda Pharmaceuticals U.S.A., Inc. | TRINTELLIX (Drug) | Food and Beverage | In-kind items and services | $21.39 | General |
| Category: NEUROSCIENCE | ||||||
| 11/06/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $3.89 | General |
| Category: PSYCHIATRY | ||||||
| 11/05/2024 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $21.93 | General |
| Category: PSYCHIATRY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 11 | 887 | 3,407 | $361,325 | $162,544 |
| 2022 | 11 | 680 | 2,227 | $282,588 | $122,114 |
| 2021 | 12 | 879 | 2,586 | $307,080 | $151,863 |
| 2020 | 13 | 1,406 | 5,575 | $445,530 | $246,565 |
Total Patients
3,852
Total Services
13,795
Medicare Billing
$683,086
Procedure Codes
49
All Medicare Procedures & Services
49 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 238 | 1,265 | $189,750 | $72,123 | 38.0% |
| 99490 | Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 104 | 744 | $55,800 | $33,365 | 59.8% |
| 99439 | Chronic care management services for two or more chronic conditions, additional 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 103 | 688 | $44,720 | $24,073 | 53.8% |
| 99497 | Advance care planning, first 30 minutes | Office | 2023 | 116 | 117 | $14,625 | $7,921 | 54.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 57 | 87 | $15,225 | $7,587 | 49.8% |
| 99484 | Care management services for behavioral health conditions, 20 minutes or more clinical staff time directed by health care professional | Office | 2023 | 34 | 233 | $13,980 | $7,371 | 52.7% |
| 90792 | Psychiatric diagnostic evaluation with medical services | Office | 2023 | 47 | 47 | $14,100 | $5,825 | 41.3% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 43 | 43 | $7,095 | $2,234 | 31.5% |
| G0438 | Annual wellness visit; includes a personalized prevention plan of service (pps), initial visit | Office | 2023 | 12 | 12 | $2,940 | $892.31 | 30.4% |
| 80305 | Testing for presence of drug, read by direct observation | Office | 2023 | 65 | 69 | $2,070 | $845.23 | 40.8% |
| 96127 | Assessment of emotional or behavioral problems | Office | 2023 | 68 | 102 | $1,020 | $307.38 | 30.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 264 | 1,447 | $207,525 | $82,759 | 39.9% |
| 99490 | Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2022 | 41 | 282 | $21,006 | $12,774 | 60.8% |
| 90792 | Psychiatric diagnostic evaluation with medical services | Office | 2022 | 53 | 53 | $15,870 | $7,846 | 49.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 55 | 79 | $13,825 | $6,851 | 49.6% |
| 93922 | Ultrasound study of arm and leg arteries | Office | 2022 | 34 | 68 | $8,364 | $3,919 | 46.8% |
| 95923 | Testing of autonomic (sympathetic) nervous system function | Office | 2022 | 34 | 34 | $6,363 | $3,186 | 50.1% |
| 95921 | Testing of autonomic nervous system function and heart rate response to deep breathing | Office | 2022 | 34 | 34 | $4,080 | $2,236 | 54.8% |
| 99439 | Chronic care management services for two or more chronic conditions, additional 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2022 | 31 | 41 | $2,665 | $1,459 | 54.7% |
| 80305 | Testing for presence of drug, read by direct observation | Office | 2022 | 34 | 35 | $1,050 | $434.42 | 41.4% |
| 96127 | Assessment of emotional or behavioral problems | Office | 2022 | 85 | 134 | $1,340 | $374.42 | 27.9% |
| 99406 | Smoking and tobacco use intensive counseling, 4-10 minutes | Office | 2022 | 15 | 20 | $500.00 | $275.39 | 55.1% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 299 | 1,678 | $205,850 | $99,606 | 48.4% |
| 93922 | Ultrasound study of arteries of both arms and legs, limited | Office | 2021 | 77 | 166 | $20,418 | $10,005 | 49.0% |
| 90792 | Psychiatric diagnostic evaluation with medical services | Office | 2021 | 65 | 65 | $16,250 | $8,681 | 53.4% |
About Dr. Adonis Al-Botros, MD
Dr. Adonis Al-Botros, MD is a Psychiatry healthcare provider based in Oklahoma City, Oklahoma. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/30/2006. The National Provider Identifier (NPI) number assigned to this provider is 1316994551.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Adonis Al-Botros, MD has received a total of $85,007 in payments from pharmaceutical and medical device companies, with $6,744 received in 2024. These payments were reported across 1,376 transactions from 39 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($58,229).
As a Medicare-enrolled provider, Al-Botros has provided services to 3,852 Medicare beneficiaries, totaling 13,795 services with total Medicare billing of $683,086. Data is available for 4 years (2020–2023), covering 49 distinct procedure/service records.
Ad
Practice Information
- Specialty Psychiatry
- Location Oklahoma City, OK
- Active Since 05/30/2006
- Last Updated 02/24/2012
- Taxonomy Code 2084P0800X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1316994551
Products in Payments
- CAPLYTA (Drug) $25,524
- VRAYLAR (Drug) $24,531
- LATUDA (Drug) $10,178
- SPRAVATO (Drug) $5,324
- REXULTI (Drug) $2,273
- PERSERIS (Drug) $2,218
- AUSTEDO (Drug) $1,656
- ARISTADA (Drug) $1,324
- HETLIOZ (Drug) $1,246
- INVEGA SUSTENNA (Drug) $1,106
- ABILIFY MAINTENA (Drug) $959.20
- INGREZZA (Drug) $723.78
- TRINTELLIX (Drug) $697.98
- Adzenys XR-ODT (Drug) $487.77
- Austedo XR (Drug) $468.52
- Fanapt (Drug) $462.87
- Aristada 441 mg (Drug) $392.54
- Qelbree (Drug) $388.41
- APLENZIN (Drug) $337.91
- VYVANSE (Drug) $318.86
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Psychiatry Doctors in Oklahoma City
Louise Thurman, M.d, M.D
Psychiatry — Payments: $318,181
Psychiatry $318,181
Willis Holloway, M.d, M.D
Psychiatry — Payments: $196,844
Psychiatry $196,844
Dr. Marvin Peyton, M.d, M.D
Psychiatry — Payments: $77,168
Psychiatry $77,168
Dr. Bradley Grinage, M.d, M.D
Psychiatry — Payments: $36,928
Psychiatry $36,928
Dr. Janita Ardis, M.d, M.D
Psychiatry — Payments: $16,017
Psychiatry $16,017
Haisam Al-Khouri, Md, MD
Psychiatry — Payments: $11,958
Psychiatry $11,958